I’m excited to share a more detailed look into my professional journey and the work I’ve been fortunate to lead at the intersection of AI, data science, and drug discovery. Over the years, I’ve focused on building data-driven strategies and platforms that help translate complex biological data into meaningful therapeutic impact. I’m grateful for the opportunity to collaborate with incredible teams and contribute to innovation in biotech. Here is my biography.

After more than three decades in biotechnology and immuno-oncology, I’ve had the privilege of contributing to the discovery and development of several antibody therapeutics and innovative biologics programs. My career has taken me from academic research to leadership roles at companies such as Bristol-Myers Squibb, Medarex, Takeda/Maverick Therapeutics, and 4D Molecular Therapeutics, where I’ve worked alongside talented teams to advance new therapies for patients. I’m excited to continue advising companies and exploring opportunities to contribute at the board level. Here is my biography.

I am pleased to share a deeper look into my professional journey and the experiences that have shaped my career across global drug discovery, biotechnology, and scientific leadership. Over the past several decades, I’ve had the privilege of contributing to meaningful research, guiding innovative teams, and supporting the growth of emerging therapeutic programs around the world. Here is my biography.

I’m pleased to share a more complete picture of my journey across structural chemistry and biology, drug discovery, higher education leadership, and diversity, equity, and inclusion work. Over the past several decades I’ve been fortunate to help build research infrastructure, launch student-success and DEI initiatives, and serve organizations committed to social and educational justice. As I move into the next chapter of advisory and board service, I remain committed to advancing opportunities for students, scientists, and communities who have too often been overlooked. Here is my biography.

I am excited to share my professional biography, which reflects my 30+ year journey across life sciences, software innovation, and executive leadership. From my early days in medicinal chemistry to my current work as a strategic advisor and board member, my career has been dedicated to helping companies grow, innovate, and navigate complex markets.

After decades of leadership in pharmaceutical R&D, I’m excited to share a detailed look at my career journey—from drug discovery to biomarker development, strategic consulting, and beyond. I’ve been fortunate to work alongside exceptional teams and contribute to the development of transformative therapies. Here is my biography.

Over the course of my career, I’ve been privileged to serve in roles that blend scientific discovery, corporate leadership, and global health impact. From developing the first anti-TNF inhibitor to founding multiple biotech companies and leading critical medical research in the U.S. Navy, my work has always centered on advancing therapies that change lives. I’m excited to share a detailed look at my professional journey, values, and vision for the future. Here is my biography.

Over the years, I’ve been fortunate to engage in cancer research, genomics, and international mentorship while working across the US, UK, Europe, India, and Nepal. From molecular oncology to nonprofit innovation, each chapter has been guided by my passion for advancing healthcare and supporting the next generation of scientists. Here is my biography.

Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Peter Payne is a highly accomplished executive with over 30 years of leadership experience in the pharmaceutical, biotechnology, and contract research organization (CRO) industries. Known for his integrity and results-driven approach, Peter has successfully led organizations through periods of significant growth and transformation. With deep expertise in drug development, clinical trials, and corporate strategy, he has built a strong reputation for driving innovation and strategic partnerships. His leadership spans notable roles, including Vice President at Optum, President of Gennaker Bio, and CEO at multiple biotech companies. Peter’s ability to communicate complex strategies and foster cross-functional collaboration has made him a respected figure in the life sciences industry.

Michael Ekstut is a seasoned business leader with over 30 years of experience in the life sciences industry, specializing in drug discovery, development, and regulatory strategy. He has held senior leadership roles at industry-leading companies, including Certara, where he guided the company’s commercial and product strategy in the regulatory and access sector. Michael is known for his strategic vision and ability to drive innovation, optimizing clinical development programs and supporting biopharma companies in navigating complex regulatory landscapes. His deep expertise in business consulting, technology, and operational management has enabled him to successfully advise executives and investors across pharmaceuticals, biotechnology, and medical devices. Currently serving as a Senior Advisor at InSilicoTrials, Michael continues to leverage his vast experience to help organizations maximize the impact of their clinical development programs and investments.

Quynh Ton is a dedicated and resilient molecular and cellular developmental biologist with over 10 years of experience in the biotech industry. Known for her integrity and commitment to improving patient care, Quynh combines her extensive knowledge in drug discovery, gene therapy, and antibody development with a proven track record in business development. She has successfully secured significant contracts, demonstrating her strategic acumen and ability to drive initiatives within her field. Quynh's exceptional communication skills enable her to convey complex scientific concepts clearly, fostering collaboration across diverse teams and stakeholders. Her passion for advancing scientific knowledge and delivering impactful solutions positions her as a valuable asset in any organization.